KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) EBT Margin (2016 - 2026)

Neogenomics filings provide 17 years of EBT Margin readings, the most recent being 9.42% for Q1 2026.

  • On a quarterly basis, EBT Margin rose 585.0% to 9.42% in Q1 2026 year-over-year; TTM through Mar 2026 was 13.7%, a 200.0% decrease, with the full-year FY2025 number at 15.16%, down 295.0% from a year prior.
  • EBT Margin hit 9.42% in Q1 2026 for Neogenomics, down from 6.52% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 6.52% in Q4 2025 to a low of 45.37% in Q1 2022.
  • Median EBT Margin over the past 5 years was 15.27% (2025), compared with a mean of 18.46%.
  • Biggest five-year swings in EBT Margin: tumbled -9314bps in 2022 and later skyrocketed 2080bps in 2023.
  • Neogenomics' EBT Margin stood at 18.4% in 2022, then soared by 47bps to 9.83% in 2023, then grew by 5bps to 9.38% in 2024, then surged by 30bps to 6.52% in 2025, then crashed by -44bps to 9.42% in 2026.
  • The last three reported values for EBT Margin were 9.42% (Q1 2026), 6.52% (Q4 2025), and 14.05% (Q3 2025) per Business Quant data.